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Abstract 
New conjugated vaccines against Streptococcus pneumoniae are being developed using pneumococcal surface 
proteins as carriers. The pneumococcal surface protein A (PspA) was selected as carrier because it is indispensable 
for virulence of S. pneumoniae. The PspA can be classified into 3 families according to the homology of protein 
sequences, within each family there is immunological cross-reactivity and PspA from family 1 or 2 are present in 
99% of strains associated with pneumococcal invasive disease. Hence, the purpose of this work was to develop an 
industrial production and purification process of His-tagged recombinant fragment of PspA in E. coli BL21 (DE3), 
rfPspA245 from family 1.  
Fed-batch cultivations in 5-L bioreactors with defined medium were carried out using glycerol as carbon source. It 
was obtained circa 60 g/L of dry cell weight and 3.0 g/L of rfPspA. Cells were disrupted with 96.7% of efficiency by 
high pressure continuous homogenizer. The clarification step was done by centrifugation. The results of 
chromatographic steps were analyzed by densitometry of SDS-PAGE protein bands. Using the chromatographic 
sequence anion exchange (Q-Sepharose) followed by metal affinity (IMAC-Sepharose), the rfPspA245 was obtained 
with 67% and 97% of purity respectively for each step and final recovery of 23%. In conclusion, the purification 
process was developed and rfPspA245 was obtained with high purity, but the recovery should still be improved. 
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1. Introduction 
Streptococcus pneumoniae is a Gram-positive microorganism with a polysaccharide capsule, causative 
agent of bacterial pneumonia, otitis media, meningitis and sinusitis. It is a human pathogen transmitted 
from person to person by aerosol.  
The incidence of pneumococcal disease and mortality is higher in children under 5 years of age, in the 
elderly and in immunocompromised individuals [1, 2]. A mortality rate of 5 - 22% has been associated 
with the initial phase of the disease and even in cases with antibiotic susceptible strains; there is still a 
mortality of 10% in pneumonia and 30% in meningitis [3], more frequent in the first months of life [4]. 
This situation is worse when chemotherapy fails due to resistant strains [5].  
The most important pneumococcal virulence factor is the capsular polysaccharide, whose structure 
defines the serotypes. In Brazil, there are 12 prevalent serotypes, which are responsible for 75% of the 
pneumococcal infections, and 45% of the pneumococcal infections are related to the serotypes 14, 6B and 
1. The serotypes 1 and 6B are prevalent in all ages; the serotype 14 is prevalent in children and the 3 and 
4 in adults [4]. 
Nomenclature 
PspA Pneumococcal surface protein A  
IMAC immobilized metal-ion affinity chromatography 
kan kanamycin 
HCD high cell density 
OD optical density 
HPLC high performance liquid chromatography 
SDS sodium dodecyl sulfate 
PAGE polyacrylamide gel electrophoresis 
ms(t)  glycerol mass flow rate (g/h) 
YX/S yield factor on biomass (g dry cell weight/g consumed glycerol) 
µset desired specific growth rate during the fed-batch phase (h
-1)
m maintenance coefficient (0.025 g/g.h) 
XF cell concentration at the beginning of feeding (g dry cell weight/L) 
VF medium volume (L) at the beginning of feeding 
tF instant at the beginning of feeding (h) 
t time 
IPTG isopropyl E-D-thiogalactopyranoside 
PMSF phenylmethylsulfonyl fluoride 
kDa kilo Daltons 
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So far all the current pneumococcal available vaccines are based on free capsular polysaccharides or 
polysaccharides conjugated to carrier proteins. Conjugation of the polysaccharide with carrier proteins 
induces T-cell dependant immunity, high antibody production and memory B-cells. The first used 
conjugated pneumococcal vaccine was licensed in 2000 (Prevenar, Wyeth) containing 7 serotypes (4, 6B, 
9V, 14, 18C, 19F e 23F) conjugated with a mutated diphtheria toxin, CRM197. This formulation has been 
effective against the pneumococcal invasive disease in children lower than 2 years old [6]. The more 
commonly used carrier proteins are the tetanus and diphtheria toxoids [7], the genetically mutated 
diphtheria toxin CRM197 [8] and the outer membrane protein complex of Neisseria meningitidis [9]. 
Although the conjugated pneumococcal vaccines are highly considered in the invasive infection, the 
variability of serotypes continues to be an obstacle [10], technically limiting the number of possible 
antigens included in the vaccine [11]. 
In order to broaden the coverage of the vaccine, a new conjugate vaccine using the three most 
prevalent polysaccharides in Brazil, serotypes 14, 6B and 1, conjugated to PspA are being developed. The 
PspA was shown to induce systemic antibody response and protection against challenge with a virulent 
strain in mice by a mechanism of inhibition of complement deposition in the bacterial surface. 
Furthermore, since the PspA structure is like a long tail, there is a region which is not covered by the 
capsule [12]. The N-terminal region of PspA contains most of the immunogenic epitopes of this molecule 
[13] and is capable of protecting mice against an invasive challenge with virulent pneumococci [14]. 
However, this region exhibits serological variability, leading to the classification of the protein in three 
families. The family 1 consists of clades 1 and 2, family 2 of clades 3, 4 and 5, and family 3 of clade 6 
[15]. The families 1 and 2 are present in around 99% of pneumococcal strains; therefore the N-terminal 
region of one representative of family 1, PspA245 was chosen to be cloned in Escherichia coli in order to 
develop the production process for the carrier proteins of this new conjugate pneumococcal vaccine. 
E. coli is the bacterium most used in expression of heterologous protein. This system allows obtaining 
high-density cell cultures [16]. However, rarely, the recombinant protein is obtained in the broth culture. 
So, it is necessary to lyse the cells to extract the protein of interest. Due the enormous amount of 
impurities released by the lysis, several purification steps are necessary. After lysis, clarification and 
chromatographic steps are employed. The right choice of chromatographic conditions can generate the 
protein in high yield and purity degree [17]. Ion exchange chromatography is widely used because is 
simple to operate, allows a greater flow and has a lower cost. Despite of higher cost, immobilized metal-
ion affinity chromatography (IMAC) is also very common due to the fact His-tagged recombinant 
proteins, as the fragments of PspA which were synthesized with six histidine residues, have affinity for 
metals like Ni+2 [18].  
2. Materials and Methods 
2.1. Production of rfPspA245 in E. coli BL21(DE3) 
The N-terminal fragment of pspA245 gene was cloned into pET37b+ and expressed in E. coli
BL21(DE3). The frozen stock was spread in agar M9 medium with kanamycin (kan). High cell density 
(HCD) medium [19] containing 20 g/L glycerol was used for cultivation of the inoculum and the same 
medium with 40 g/L glycerol was used for batch cultures in 5L-reactor BioFlo 2000 (New Brunswick). 
The cell concentration was measured by OD600nm. The glycerol and acids concentrations were analyzed 
by HPLC (Aminex HPX-87H, BioRad) and the protein by SDS-PAGE 12%. The mass flow rate of the 
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carbon source during the fed-batch phase was calculated according to the equation (1) and the induction 
was done with 1 mM IPTG. 
     (1) 
2.2. Purification of rfPspA245 produced in E. coli BL21(DE3) 
After the cultivation, the cellular suspension was centrifuged (17,969 g) by 30 minutes at 4°C. The cell 
mass was frozen. The cell pellets (400g) were resuspended in 1.0 L of lysis buffer (25 mM tris pH 8.0 + 
0.1% triton X-100) with a protease inhibitor, 1.0 mM PMSF. A homogeneous suspension was obtained in 
a mixer (CAT X520) and disrupted by a high pressure continuous homogenizer (APV-Gaulin) in a close 
loop for 12 minutes at 600 bar. The homogenizer has a jacketed reservoir and a tube-and-shell heat 
exchanger in the inlet and outlet, respectively, to control the temperature during the lysis under 12°C. 
Samples were taken every minute to determine the efficiency of lysis. The 100% of lysis efficiency was 
considered the OD600nm of the cell suspension after treatment with 0.1M NaOH. 
The homogenate clarification was done by centrifugation (17,696 g) for 2 h at 4°C. The supernatant 
was filtrate in a membrane (0.45 µm) to obtain the clarified homogenate.  
The chromatographic steps were done using an Äkta Explorer (GE Heathcare). The flow was 50 
mL/min in columns XK 50. The resins employed were Q-Sepharose Fast Flow (anion exchange) and 
IMAC-Sepharose (immobilized metal-ion affinity chromatography). All material was purchased from GE 
Healthcare. 
We evaluated two chromatographic sequences: Q-Sepharose followed by IMAC-Sepharose and 
IMAC-Sepharose followed by Q-Sepharose. In the case of Q-Sepharose, the elution buffer was 25 mM 
sodium acetate pH 6.5 + 200 mM NaCl. IMAC-Sepharose was loaded with NiSO4 and the elution was 
done with 20 mM phosphate buffer pH 7.4 + 200 mM imidazol. The conditions of binding, wash, elution 
and cleaning are showed in Figure 1 (Q-Sepharose) and Figure 2 (IMAC-Sepharose). 
Fig. 1. Chromatographic conditions used for purification of rfPspA245 in Q-Sepharose. 
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Fig. 2. Chromatographic conditions used for purification of rfPspA245 in IMAC-Sepharose. 
2.3. Analytical Methods 
Protein quantification was done according to Bradford [20], using Bradford reagent from Sigma-
Aldrich.  SDS-PAGE was carried out under reducing conditions in a 12% gel according to Laemmli et al. 
[21]. The relative purity, considered as the percentage of the intensity of PspA245 band against the sum 
of intensity of all other bands in the lane, was determinate by densitometry of SDS-PAGE protein bands 
in a Biorad GS-800 densitometer and analyzed by Quantity One 4.6.3 software. 
3. Results and Discussion 
The rfPspA245 was produced using glycerol, a by-product of the Brazilian biofuel industry. It was 
obtained circa 60 g/L of dry cell weight and 3.0 g/L of rfPspA.  Using glycerol as carbon source, the 
acetate formation was lower than 1.0 g/L during all process (not shown). The biomass production was 
similar to that previously obtained using glucose as carbon source (not shown).  
The Figure 3 shows the rfPspA245 production in high cell density of E. coli using glycerol as carbon 
source.
Fig. 3. Production of rfPspA245 in fed-batch cultures using glycerol as carbon source. Lane 1: before induction; lanes 2-5: 1-4 h of 
induction, respectively. 
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The cell disruption was successfully achieved using a mechanical (high pressure continuous 
homogenizer) and chemical (detergent Triton X-100) combined method, reaching 96.7% of efficiency. 
The first chromatographic sequence, Q-Sepharose followed by IMAC-Sepharose, was used to the 
purification rfPspA245. The conditions were described above (Figures 1 and 2). The electrophoresis gels 
of purification are shown in Figure 4 and 5. The results are described in Table 1. 
Considering the results described in Figure 4, 5 and Table 1, we can verify that the protein is not 
present in fraction QF1 but in fraction QF2 is present with higher purity, 44.8%, than in loading fraction 
34.9%.  In the trade off, the purity was selected instead of recovery and the QF3 fraction was obtained 
with a purity of 88.1%. 
Fig. 4. SDS-PAGE of rfPspA245 purification in Q-Sepharose. Lane 1: molecular marker (kDa); lane 2: clarified homogenate; lane 
3: Q loading fraction; lane 4: QF1, flow-through; lane 5: QF2, wash 1; lane 6: QF3, elution; lane 7: QF4, wash 2; lane 8: QF5, 
cleaning.
Fig. 5. SDS-PAGE of rfPspA245 purification in IMAC-Sepharose. Lane 1: IMAC loading fraction; lane 2: NiF1, flow-through; lane 
3: NiF2, wash 1; lane 4: NiF3, wash 2; lane 5: NiF4, elution; lane 6: molecular marker (kDa). 
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Table 1. Purification of rfPspA245 in Q-Sepharose followed by IMAC-Sepharose 
Sample 
Total Protein 
(mg) 
Relative Purity 
rfPspA245 (%)#
rfPspA245 (mg) 
Recovery 
rfPspA245 (%) 
Purification 
Factor 
Clarified Homogenate 62010 34.9 21641 100.0 1.0 
Q-Sepharose (QF3) 10120 88.1 8916 41.2 2.5 
IMAC –Sepharose (NiF4) 5200 96.6 5023 23.0 2.8 (1.1)* 
# Calculated by densitometry.  * Value between parentheses is the purification factor of this step 
In the first chromatographic sequence tested for purification of PspA245, we obtained the necessary 
purity degree after the IMAC-Sepharose (96.9%). However, the recovery of PspA245 was low (23%). 
Analyzing the SDS-PAGE (Figure 5) we can observe PspA245 in all fractions of IMAC-Sepharose. So, 
the chromatographic conditions could be changed in order to increase the recovery. 
The second chromatographic sequence tested for purification of PspA245consisted of IMAC-
Sepharose followed by Q-Sepharose. The conditions are the same described in Figures 1 and 2. The 
Figures 6 and 7 and Table 2 show the results. This chromatographic sequence was not indicated to the 
purification of rfPspA245. The relative purity (79.9%) and the final recovery (9.1%) were lower than 
using the inverse sequence. 
Besides the better results obtained with the first chromatographic sequence (Q-Sepharose followed by 
IMAC-Sepharose), the use of Q-Sepharose as the first chromatographic step has the advantage of 
increasing the life-time of the most expensive resin, IMAC-Sepharose. 
Fig. 6. SDS-PAGE of rfPspA245 purification in IMAC-Sepharose. Lane 1: molecular marker (kDa); lane 2: clarified homogenate; 
lane 3: NiF1, flow-through; lane 4: NiF2, wash; lane 5: NiF3, elution.
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Fig. 7. SDS-PAGE of rfPspA245 purification in Q-Sepharose. Lane 1: molecular marker (kDa); lane 2: Q loading fraction; lane 3: 
QF1, flow-through; lane 4: QF2, wash 1; lane 5: QF3, wash 2; lane 6: QF4, elution; lane 7: QF5, cleaning. 
Table 2. Purification of rfPspA245 in IMAC-Sepharose followed by Q-Sepharose. 
Sample 
Total Protein 
(mg) 
Relative Purity 
rfPspA245 (%)#
rfPspA245 
(mg) 
Recovery 
rfPspA245 (%) 
Purification Factor 
Clarified Homogenate 53872 44.0 23704 100.0 1.0 
IMAC-Sepharose (NiF3) 4100 68.5 2808 11.8 1.5 
Q- Sepharose (QF4) 2700 79.9 2157 9.1 1.8 (1.2)* 
# Calculated by densitometry.  * Value between parentheses is the purification factor of this step. 
4. Conclusions 
The PspA245 was produced in a high cell density cultivation of E. coli, the cells were disrupted with 
high efficiency and the best sequence for the purification of recombinant PspA was Q-Sepharose 
followed by IMAC-Sepharose. 
The purification processes still need to be improved, especially in the recovery from IMAC 
chromatography and may be also in the recovery of Q-Sepharose, but it is noteworthy that PspA245 was 
obtained with purity of 96.6%.   
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